Introduction: Prevention of visual impairment due to congenital cataract is an international priority as part of VISION 2020 - The Right to Sight, the joint initiative of the World Health Organization and the International Agency for the Prevention of Blindness. The present study is part of the Epidemiology and Safety (EPISAFE) collaborative program aiming at assessing the epidemiology and safety of interventions in ophthalmology. Methods: All children who underwent cataract surgery before the age of 1 year in France between January 2010 and December 2012 were identified by using the Programme de Médicalisation des Systèmes d'Information. Results: In 3 years, 532 children (699 eyes; 46.6% girls) had cataract surgery before the age of 1 year; 31.4% had bilateral surgery. During the first year of life, the incidence of cataract surgery was 2.15/10,000 births. The median (interquartile range) age at surgery was 3.5 (2.2-4.8) months for children with unilateral cataract and 4.0 (2.2-7.2) months for children with bilateral cataract. Of the 699 operated eyes, 76.49% received intraocular lens implantation during the cataract surgery. Conclusions: The incidence of congenital cataract surgery observed in France is close to that in the literature in the industrialized world, which is estimated at 1-3/10,000 births. The timing of surgery is critical for visual development. Surgery was performed younger in children with monocular cataracts than in those with bilateral cataracts.

Keywords:
Congenital cataract, Incidence, Implant, Timing
1.
Foster A, Gilbert C: Cataract in children. Acta Paediatr 2003;92:1376-1378.
2.
Daien V, Le Pape A, Heve D, Carriere I, Villain M: Incidence and characteristics of cataract surgery in France from 2009 to 2012: a national population study. Ophthalmology 2015;122:1633-1638.
3.
Foster A, Gilbert C, Rahi J: Epidemiology of cataract in childhood: a global perspective. J Cataract Refract Surg 1997;23(suppl 1):601-604.
4.
Rahi JS, Dezateux C; British Congenital Cataract Interest Group: Measuring and interpreting the incidence of congenital ocular anomalies: lessons from a national study of congenital cataract in the UK. Invest Ophthalmol Vis Sci 2001;42:1444-1448.
5.
Wiesel TN: Postnatal development of the visual cortex and the influence of environment. Nature 1982;299:583-591.
6.
Chak M, Rahi JS; British Congenital Cataract Interest Group: Incidence of and factors associated with glaucoma after surgery for congenital cataract: findings from the British Congenital Cataract Study. Ophthalmology 2008;115:1013-1018.e2.
7.
Lambert SR, Purohit A, Superak HM, Lynn MJ, Beck AD: Long-term risk of glaucoma after congenital cataract surgery. Am J Ophthalmol 2013;156:355-361.e2.
8.
Serafino M, Trivedi RH, Levin AV, Wilson ME, Nucci P, Lambert SR, et al: Use of the Delphi process in paediatric cataract management. Br J Ophthalmol 2016;100:611-615.
9.
Tadros D, Trivedi RH, Wilson ME: Primary versus secondary IOL implantation following removal of infantile unilateral congenital cataract: outcomes after at least 5 years. J AAPOS 2016;20:25-29.
10.
Chak M, Wade A, Rahi JS; British Congenital Cataract Interest Group: Long-term visual acuity and its predictors after surgery for congenital cataract: findings of the British Congenital Cataract Study. Invest Ophthalmol Vis Sci 2006;47:4262-4269.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.